Abstract
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.
Original language | English |
---|---|
Article number | 8 |
Journal | Current Atherosclerosis Reports |
Volume | 18 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2016 |
Externally published | Yes |
Keywords
- Cardiovascular disease
- Ezetimibe
- Low-density lipoprotein cholesterol